Navigation Links
Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
Date:3/5/2009

AAD Launches include New Technologies, Innovative Applications and New Clinical Data

SAN FRANCISCO, March 5 /PRNewswire/ -- Aesthera today announced several new launches at the upcoming 67th annual meeting of the American Academy of Dermatology in San Francisco, CA. Aligned with the company's strategic imperative to stay at the forefront of innovations in skin management, the launches will focus on the company reinforcing its leadership as the premier device based solution for acne as well as the development and commercialization of innovative technological solutions for high demand patient procedures.

Strengthening Position as Leading Acne Treatment

Strengthening its leadership position as a premier treatment in the battle against acne, Aesthera announced its latest peer reviewed clinical paper titled "Treatment of Acne with Photopneumatic Therapy," by Tina S. Alster MD et al which is published in the March 2009 issue of the Journal of Drugs and Dermatology. The paper studies the clinical efficacy of Photopneumatic Therapy for the treatment of mild to severe facial acne. "Our study noted greatest improvement in patients with severe acne. We are pleased with treatment outcomes, especially for severe acne," said study co-investigator Dr. Alster. The study was performed using Aesthera's ISOLAZ system, the only FDA cleared device for the treatment of Comedonal and Pustular Acne.

Profusion Skin Therapy for Acne, Skin Rejuvenation and Body Tightening

Aesthera will launch Profusion(TM) - (Pro=Professional and Fusion=Combination) - a breakthrough skin therapy that combines the proven clinical benefits of Photopneumatic light treatments with the delivery of Aesthera's proprietary skincare to symbiotically enhance skin treatment outcomes for acne, skin rejuvenation and body tightening. "Profusion's novel mechanism has tremendous therapeutic potential for innovative new applications. We are very excited about its clinical potential," says Vic Narurkar, MD, Chair of Dermatology at the California Pacific Medical Center (CPMC) in San Francisco, CA. "Profusion Skin Therapy is the fastest growing procedure in our practice. We routinely perform it in combination with the majority of skin treatments we offer," he adds. New applications of the technology include body tightening and skin lightening.

Additionally, Aesthera will release results of a multi-year scientific collaboration with the University of California at Riverside on Profusion Skin Therapy. "Our collaboration with the UC Riverside team reflects our commitment to basing all our treatment solutions on solid science," says Robert Anderson, PhD, Co-Founder and Chief Technical Officer of Aesthera. "We are very excited about expanding the commercial applications of Profusion Skin Therapy and are working on future applications of this novel technology," he added.

Innovative Body Tightening Technology

Moving beyond existing frameworks that address and treat body tightening, shaping and contouring Aesthera will be previewing a revolutionary approach to body tightening technology. The company's innovative body tightening platform (pending FDA clearance) will utilize a unique delivery mechanism and state of the art applicator that allows for high treatment precision and focused energy delivery. The patient benefits of Aesthera's unique solution will be fast, painless, and extremely precise treatments.

"Our continuous development and commercialization of solutions reflects our commitment to growing and strengthening our leadership position in the dermatology market," said Alon Maor, Aesthera's President & CEO.

In addition, to the above launches, Aesthera's technology will be included in over 11 podium presentations by thought leaders in dermatology.

For a complete list of podium presentations, or for more information on Profusion Skin Therapy or Isolaz Light Treatments, visit www.AESTHERA.Com, www.ISOLAZ.com, call 877.275.4779, or email WeListen@AESTHERA.com.

About Photopneumatic(TM) Technology

Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.

About Aesthera Corporation

Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology. Clinically proven to be pain-free and up to seven times faster than currently available light-based aesthetic systems, Aesthera's revolutionary systems combine the proven properties of therapeutic light with gentle pneumatic energy to more effectively work on dermal and epidermal skin targets.

    Contact:
    Sarvar Kothavala
    Aesthera Corp.
    415.760.0902
    SKothavala@Aesthera.com


'/>"/>
SOURCE Aesthera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: